Greenlight Biosciences Holdings Stock Beta
Greenlight Biosciences Holdings fundamentals help investors to digest information that contributes to Greenlight Biosciences' financial success or failures. It also enables traders to predict the movement of Greenlight Stock. The fundamental analysis module provides a way to measure Greenlight Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Greenlight Biosciences stock.
Greenlight |
Greenlight Biosciences Holdings Company Beta Analysis
Greenlight Biosciences' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Greenlight Biosciences Beta | 1.44 |
Most of Greenlight Biosciences' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Greenlight Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Greenlight Biosciences Holdings has a Beta of 1.44. This is 67.44% higher than that of the Biotechnology sector and 3.6% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Greenlight Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenlight Biosciences' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenlight Biosciences could also be used in its relative valuation, which is a method of valuing Greenlight Biosciences by comparing valuation metrics of similar companies.Greenlight Biosciences is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Greenlight Biosciences will likely underperform.
Greenlight Fundamentals
| Return On Equity | -3.67 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (14.94) % | |||
| Current Valuation | 90.5 M | |||
| Shares Outstanding | 151.68 M | |||
| Shares Owned By Insiders | 42.90 % | |||
| Shares Owned By Institutions | 26.85 % | |||
| Number Of Shares Shorted | 1.03 M | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 41.41 X | |||
| Revenue | 6.38 M | |||
| Gross Profit | (87.22 M) | |||
| EBITDA | (153.99 M) | |||
| Net Income | (167.06 M) | |||
| Cash And Equivalents | 44.13 M | |||
| Cash Per Share | 0.36 X | |||
| Total Debt | 80.48 M | |||
| Debt To Equity | 2.30 % | |||
| Current Ratio | 1.16 X | |||
| Book Value Per Share | 0.14 X | |||
| Cash Flow From Operations | (136.73 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.12) X | |||
| Target Price | 0.6 | |||
| Number Of Employees | 10 | |||
| Beta | 1.44 | |||
| Market Capitalization | 45.43 M | |||
| Total Asset | 148.6 M | |||
| Retained Earnings | (420.64 M) | |||
| Working Capital | 35.75 M | |||
| Z Score | -6.71 | |||
| Net Asset | 148.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Greenlight Stock
If you are still planning to invest in Greenlight Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Greenlight Biosciences' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |